Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Next Previous
X
Search
Trial Profile

Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Entinostat (Primary) ; Exemestane
  • Indications Advanced breast cancer; Carcinoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Kyowa Kirin

    • Most Recent Events

    • 06 Jan 2023 Primary endpoint (Progression Free Survival(PFS) defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1)) has not been met, as per results published in the Japanese Journal of Clinical Oncology.
    • 06 Jan 2023 Interim and final results assessing the efficacy and safety of the oral histone deacetylase inhibitor entinostat in Japanese patients with hormone receptor-positive advanced/recurrent breast cancer and to explore potential biomarkers, published in the Japanese Journal of Clinical Oncology.
    • 17 Jun 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top